Last reviewed · How we verify
E2511
At a glance
| Generic name | E2511 |
|---|---|
| Sponsor | Eisai Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants (PHASE1)
- A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E2511 CI brief — competitive landscape report
- E2511 updates RSS · CI watch RSS
- Eisai Inc. portfolio CI